| Dawn Marie Mounce, LPN | |
|
Highway 49 South, Annapolis, MO 63620 | |
| (573) 598-4213 | |
| (573) 598-4602 |
| Full Name | Dawn Marie Mounce |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | Highway 49 South, Annapolis, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780788869 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 054114 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dawn Marie Mounce, LPN 128 Pine St, Ironton, MO 63650-9122 Ph: (573) 546-3267 | Dawn Marie Mounce, LPN Highway 49 South, Annapolis, MO 63620 Ph: (573) 598-4213 |
News Archive
Selcia has successfully completed 14C radiolabelled API projects on behalf of a diverse range of clients for phase 1 human trials, following MHRA GMP Certification in September 2010. In response to a sharp increase in demand for this specialist service, Selcia has invested to double its capacity for handling GMP radiolabelling projects.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
As a world leader in oral biology and salivary diagnostics, the Forsyth Institute is working with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative as an advisor and critical resource in the effort to develop and eventually deploy millions of accurate, rapid COVID-19 point-of-care tests used daily in schools, colleges, universities, and for testing underserved populations.
US scientists have tested a new therapeutic approach that could help eliminate dormant HIV infection that current treatments miss. The researchers report these preliminary findings in a proof-of-concept study in this week's issue of The Lancet.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
› Verified 2 days ago